Objectives: The safety of rifabutin replacing rifampicin among adults having rifampicin-related adverse reactions (ARs) during the treatment of tuberculosis remains unknown.
Introduction
Tuberculosis remains a leading health issue worldwide. 1 Modern chemotherapy can cure .95% of drug-susceptible pulmonary tuberculosis, 2 but compliance is an important factor affecting the outcome of anti-tuberculosis therapy since these regimens tend to be administered over long periods of time. Due to the excellent sterilizing capacity of rifampicin, standard short-course antituberculosis regimens contain this drug to reduce the duration of treatment and achieve low relapse rates. 2 However, rifampicinrelated adverse reactions (ARs), including hepatitis, cholestasis, dermatological events and gastrointestinal disturbances, are not rare 3, 4 and some even require rifampicin discontinuation. If rifampicin cannot be used, current recommendations suggest a prolonged anti-tuberculosis regimen of up to 12 -18 months, 5 which will be associated with a higher rate of poor adherence, recurrence and the possible emergence of resistant strains. 2 Rifabutin, a rifamycin 6 with activity against Mycobacterium tuberculosis, has been used in patients coinfected with tuberculosis and HIV, as it has fewer drug -drug interactions than rifampicin. Rifabutin has activity against mycobacteria similar to that of rifampicin and in fact may be more potent. 7 Furthermore, rifabutin may have a lower incidence of severe ARs 8 than rifampicin. Thus, it may be an attractive substitute in situations where rifampicin is intolerable.
Although successful use of rifabutin in substitutions for rifampicin has previously been reported in some small case series, 9 -11 its overall safety and impacts on treatment outcomes are still unknown. We conducted this study to evaluate the safety and impact on treatment outcomes of using rifabutin to replace 
Methods
We conducted this retrospective cohort study in a tuberculosis referral hospital in southern Taiwan. All cases newly treated for tuberculosis from June 2006 to June 2010 were reviewed to identify those who had received rifabutin as part of their treatment regimen. In Taiwan, all tuberculosis patients should be registered and the recommended treatment regimen for newly diagnosed tuberculosis is a short-course (6 months) directly observed regimen, consisting of a daily four-drug combination (isoniazid, rifampicin, ethambutol and pyrazinamide) for 2 months followed by daily isoniazid, rifampicin and ethambutol for an additional 4 months. 12 Hepatitis B virus (HBV) and hepatitis virus C (HCV) infections were diagnosed by the presence of serum hepatitis B surface antigen and antibodies to HCV, respectively. Laboratory tests, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), total bilirubin and leucocyte and absolute neutrophil counts, were performed every week during the first 2 weeks and monthly thereafter until the completion of treatment. Antibodies to HIV were assayed in every patient with tuberculosis. This study was approved by the Institutional Review Board of the National Cheng Kung University Hospital (A-ER-101-152).
When ARs occurred in patients on standard short-course therapy, mild or moderate ARs were managed by changing the dosing schedule or with Rifabutin replaces rifampicin symptom-relieving medications. For more severe symptoms, all antituberculosis drugs were stopped until ARs resolved, followed by serial reintroduction of anti-tuberculosis medications. ARs were defined as follows: hepatitis was an increase in ALT and/or AST to ≥3 times the upper limit of normal (ULN) with symptoms or an increase in ALT and/or AST to 5 times the ULN without symptoms; 13 gastrointestinal intolerance included nausea, vomiting, diarrhoea or abdominal discomfort; flu-like syndrome included rigor, fever or malaise; and a dermatological event was a rash with or without pruritus. Severe ARs included severe hepatitis (defined as total bilirubin .2 or AST and/or ALT elevations ≥5 times the ULN), neutropenia [defined as absolute neutrophil count (ANC) ,1500/ mL], uveitis and life-threatening drug eruptions such as Stevens -Johnson syndrome and toxic epidermal necrosis. ARs were considered attributable to rifampicin/rifabutin if they were consistent with known rifampicin/rifabutin toxicities, resolved following the interruption of rifampicin/rifabutin and if they recurred on re-challenge or did not recur with the re-introduction of anti-tuberculosis medications other than rifampicin/rifabutin.
14 Rifabutin was administered at 300 mg daily for patients with intolerance to rifampicin. Treatment success was defined as the sum of cured and completed treatments as previously defined. 2 
Statistical analysis
Categorical variables were compared using the x 2 test or Fisher's exact test and differences in continuous variables were analysed using Wilcoxon's rank sum test or analysis of variance ('ANOVA'), where appropriate. Kaplan-Meier time-to-event analyses for severe ARs were constructed for subgroups and compared with the log-rank test. Multivariate logistic regression analysis was applied to determine the independent variables that predicted the development of severe ARs. All statistical analyses were performed using Stata version 11 software (College Station, TX, USA). Twosided P,0.05 was considered to be statistically significant.
Results
From June 2006 to June 2010, a total of 2868 tuberculosis patients newly treated in the hospital were screened. Of these patients, medical records indicated 221 (8%) patients were placed on rifabutin due to intolerable rifampicin-related ARs. There were 157 men (71%) and 64 women (29%), all of Taiwanese Han ethnicity, with a mean age of 64+20 years (Table 1) . None was seropositive for HIV infection. One hundred and seventy-eight (81%) patients had pulmonary tuberculosis, 32 (14%) had extra-pulmonary tuberculosis and 11 (5%) had both. Serological results for HBV and HCV infection were available for 174 and 201 patients, respectively; of these, 21 (12%) of those with HBV results were HBV coinfected and 41 (20%) of those with HCV results were HCV coinfected, and 53 (31%, n ¼ 173) were either HBV or HCV coinfected. Dermatological events ranked as the most common previous ARs (n¼ 82, 37%) leading to replacement of rifampicin, followed by gastrointestinal intolerance (n¼55, 25%), cholestasis (n¼ 23, 10%), hepatitis (mild, n¼ 16, 7%; severe, n¼ 23, 10%), flu-like syndrome (n¼ 12, 5%), arthralgia (n¼ 5, 2%), neutropenia (n ¼2, 1%) and others (n¼3, 1%). Among the 23 patients with severe hepatitis, 6 (26%) had jaundice.
A total of 158 (72%) patients tolerated rifabutin during antituberculosis treatment, but another 47 (21%) and 16 (7%) patients experienced mild and severe rifabutin-related ARs, respectively, and needed to discontinue rifabutin before treatment success (Table 1) . Demographic characteristics and previous rifampicin-related ARs were similar between those with and without rifabutin-related ARs. The frequencies of mild rifabutin-related ARs were as follows: dermatological events (10%), gastrointestinal intolerance (4%), flu-like syndrome (3%), arthralgia (2%), cholestasis (1%) and mild hepatitis (0.5%). The most common severe rifabutin-related ARs were neutropenia (n¼ 13, 6%), severe hepatitis (n¼ 2, 0.9%) and uveitis (n¼ 1, 0.5%; Tables 2 and 3 ). Compared with rifampicinrelated ARs, rifabutin was associated with higher rates of newonset flu-like syndrome (0.4% versus 2.7%, respectively; P,0.01) and hepatitis (0.1% versus 5.9%, respectively; P,0.01). The median time from initiating rifabutin to the development of rifabutin-related ARs (21 days) was longer in patients with previous rifampicin-related gastrointestinal intolerance (46 days) than in those with other rifampicin-related ARs (12, 21, 11, 40, 36 and 7 days for patients with previous rifampicin-related dermatological events, cholestasis, mild hepatitis, severe hepatitis, flu-like syndrome and arthralgia, respectively). The median time to the development of rifabutin-related mild ARs was 14 days (9, 4, 35, 7, 60 and 44 days for dermatological events, gastrointestinal intolerance, flu-like syndrome, arthralgia, cholestasis and mild hepatitis, respectively) and for the development of severe ARs the time was 26 days (27, 11 and 92 days for neutropenia, severe hepatitis and uveitis, respectively). A total of 29 (46%) rifabutin-related ARs (27 mild and 2 severe ARs) were recurrences of previous ARs caused by rifampicin (Table 2 and 3) and the median time to AR recurrence was 8, 4, 89, 11 and 7 days for dermatological events, gastrointestinal intolerance, cholestasis, hepatitis and arthralgia, respectively. Those who had previous rifampicin-related arthralgia, dermatological events or cholestasis had higher recurrence rates (60%, 23% and 9%, respectively) than others (5% for hepatitis and gastrointestinal intolerance and 0% for flu-like syndrome, neutropenia and others; P,0.01).
Among all patients, females had a significantly higher rate of severe ARs related to rifabutin than males (14% and 4% for females and males, respectively, P ¼0.01; Table 1 and Figure 1a) . Chien et al.
Among 173 patients having serology tests for HBV and HCV infection status, those infected with HCV or HBV also tended to have higher rates of rifabutin-related severe ARs than those without (15% versus 5%, P ¼ 0.03; Table 1 and Figure 1b) . Among 16 patients who had previous rifampicin-related mild hepatitis, 2 (12.5%) experienced severe hepatitis related to consequent rifabutin treatment. One patient with rifabutin-related severe hepatitis recovered within 9 days and another recovered within 3 weeks after rifabutin discontinuation. Among the 13 patients who had rifabutin-related neutropenia (9 with ANC ,1500/mL and 4 with ANC ,1000/mL), 10 (77%) recovered within 1 week and 2 (15%) recovered within 3 weeks, but 1 (8%) experienced persistent neutropenia for 5 weeks. No opportunistic infection was found during neutropenia. Blurred vision with uveitis was reported in one patient (0.5%), who recovered after rifabutin discontinuation. Multivariate logistic regression analysis including age, gender and status of HBVor HCVcoinfection showed that female gender and HBV or HCV coinfection were independent risk factors for rifabutin intolerance (OR 3.35, 95% CI 1.06-10.56, P¼0.04 for female gender and OR 3.72, 95% CI 1.19-11.67, P¼0.02 for HBV or HCV coinfection; Table 4 ). Compared with patients who could not tolerate rifabutin, patients who tolerated rifabutin had a significantly shorter time to treatment success (316, 389 and 449 days for groups with good tolerance, mild ARs and severe ARs, respectively, P,0.01). The rates of interruption to treatment were similar between groups. No development of new drug resistance and no relapse of tuberculosis were found during 2 years of follow-up in all patients.
Discussion
Rifabutin could be a useful alternative to rifampicin in multidrug regimens since it is a much more potent anti-tuberculosis agent than rifamycin. 7 Compared with rifampicin, rifabutin has a much Data are presented as n (%). *P, 0.05; **P,0.01.
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JAC longer half-life, wider tissue distribution and lower plasma levels, but higher intracellular penetration, 15 and could eradicate infection approximately twice as quickly as rifampicin. 16, 17 The efficacy of rifabutin as a substitute for rifampicin in the 6 month antituberculosis regimen has been documented in several clinical studies in HIV-infected patients. 7, 8, 18 Although clinical experience with rifabutin indicates that rifabutin may be no more toxic than rifampicin and may be generally well tolerated, 8 several adverse events, such as nausea, vomiting, hepatitis and flu-like syndromes, have been reported. 19 Importantly, the tolerance profile of rifabutin is distinct from that of rifampicin. 19 Gonzales-Montaner et al. 8 found that adverse events appeared to be more severe in rifampicin-containing regimens compared with rifabutin. Studies 4, 10 showed that rifabutin was well tolerated, regardless of the indications for its use, and 80% of patients who had experienced previous rifampicin-related ARs were able to complete tuberculosis treatment with rifabutin, but patients with previous rifampicin-related dermatological events had a higher risk of developing rifabutin-related ARs compared with other patients. Here, we also found that patients with previous rifampicin-related dermatological events had a higher recurrence rate (23%) after substitution with rifabutin, but it was not associated with developing other ARs.
Successful replacement of rifampicin with rifabutin has been reported after a flu-like reaction and hypersensitivity reaction to rifampicin, 10 but, because a flu-like reaction to rifampicin might be due to a type III reaction caused by anti-rifampicin antibodies, 9 the possibility of cross-reactivity between rifampicin with rifabutin has been suspected. 20 We showed that, among 12 patients with flu-like reaction (fever, malaise) caused by rifampicin, none showed recurrence with similar symptoms. Flu-like symptoms could also accompany other immunologically mediated events such as acute renal failure or haemolytic or thrombocytopenic crises, 9 but we did not find these in the present study. However, among five patients with previous rifampicin-related arthralgia, three (60%) showed recurrence of the same symptoms. The mechanism of cross-reactivity is unclear at this time. Some potential life-threatening rifabutin-related ARs, such as neutropenia, high-grade liver injury, uveitis and life-threatening dermatological events, are infrequently reported, but important. The hepatic toxicity of rifabutin might be lower than that of rifampicin. 8 A study by Mancini et al. 11 found that rifabutin could replace rifampicin in patients who experienced rifampicin-related hepatic toxicity without recurrence of liver function abnormalities.
Another recent study 4 also demonstrated that 79% of patients who had had rifampicin-related liver injury successfully completed therapy with a rifabutin-containing regimen, though two subjects had rifampicin-related high-grade liver injury. We also found that rifabutin-related hepatitis was rare (1%), and among 39 patients who had previous rifampicin-related hepatitis only 2 (5%) developed rifabutin-related severe liver injury. Although the mechanisms of drug-induced hepatitis during anti-tuberculosis treatment are not fully understood, studies have found increasing hepatitis risk during treatment of tuberculosis with a rifampicincontaining standard short-course regimen in patients with HBV or HCV coinfection. 13, 21 However, we found that the rate of rifabutin-related hepatitis among patients with HBV or HCV coinfection was not higher than in other patients. This implies that rifabutin could be a tolerable alternative choice for reintroduction instead of rifampicin when there is rifampicin-induced hepatotoxicity in patients with HBV or HCV coinfection.
Another important finding in this study is that females had a higher rate of rifabutin-related severe ARs, mainly neutropenia, than males (10.9% versus 3.8% for neutropenia; Table 3 ). Neutropenia is a rare complication of rifampicin, but occurs more commonly during treatment with rifabutin. A study by Apseloff et al. 22 found that severe neutropenia could occur among healthy volunteers receiving the usual dose of rifabutin (300 mg/day), especially among females, and that neutropenia might be caused by a direct rifabutinrelated toxic effect on the marrow. Neutropenia may be transient, 23 but, as noted in one case during our study, it can continue for several days 22 and therefore we need to pay more attention to its progress and related complications.
This study has several limitations that are worth noting. First, although tuberculosis treatment guidelines and drug challenge guidelines are well established and implemented in clinical practice, the anti-tuberculosis regimens and drug challenge methods used in this study were heterogeneous due to the retrospective design. Second, patients were monitored for neutropenia monthly after the first 2 weeks, and thus delayed neutropenia would not have been detected. Third, the number of patients with adverse effects was small, which limited the power of our analysis. Finally, none of our patients experienced severe drug eruptions related to rifampicin or rifabutin (e.g. Stevens -Johnson syndrome), so we could not address the risk factors related to these life-threatening severe ARs. Prospective, large-scale studies are warranted.
In conclusion, we found that rifabutin was well tolerated in 72% of non-HIV-infected patients who had previously had intolerable rifampicin-related ARs, and a regimen containing rifabutin could be considered as an alternative choice. Compared with those who could not tolerate rifabutin, patients who tolerated treatment with rifabutin could achieve treatment success earlier, but females and patients with HBV or HCV coinfection had a higher risk of developing rifabutin-related severe ARs; such patients require more cautious monitoring.
Funding
This study was funded by grant 10235 from the Ministry of Health and Welfare of Taiwan.
Transparency declarations
None to declare.
